e-Therapeutics plc Notice of AGM and Posting of Annual Report (3218Z)
21 Mayo 2021 - 1:00AM
UK Regulatory
TIDMETX
RNS Number : 3218Z
e-Therapeutics plc
21 May 2021
e-therapeutics plc
("e-therapeutics" or "the Company")
Notice of Annual General Meeting and Posting of Annual Report
and Accounts
Oxford, 21 May 2021 - e-therapeutics plc (AIM: ETX), the drug
discovery company, announces that its Annual Report and Accounts
for the year ended 31 January 2021, which includes the notice of
its 2021 Annual General Meeting ("AGM"), have been posted to
shareholders today and are available on the Company's website at
https://www.etherapeutics.co.uk/investors/reports-results/
The AGM will be held at 13:00 on 16 June 2021 at 17 Blenheim
Office Park, Long Hanborough, Oxfordshire, OX29 8LN with the
minimum attendance required to form a quorum. Shareholders will not
be permitted to attend the AGM in person but are encouraged to
complete proxy forms appointing the Chair of the meeting as their
proxy so that they can be represented.
Shareholders who wish to register their votes on the resolutions
to be put to the AGM should do so by completing and signing the
proxy form that accompanies the notice of the AGM (or appoint a
proxy electronically if their shares are held in CREST) in
accordance with the instructions printed on the proxy form.
Please complete and return the form of proxy in accordance with
the instructions printed thereon as soon as possible and in any
event so that it is received by the Company's registrar, Neville
Registers Limited, Neville House, Steelpark Road, Halesowen, B62
8HD not later than 13:00. on 14 June 2021.
Despite not being able to attend the AGM, the Company encourages
shareholders to ask questions and engage by e-mailing questions to
contact@etherapeutics.co.uk with the subject "AGM" no later than 11
June 2021. Questions will be considered and answered following the
AGM and the responses to questions will be provided on the
Company's website.
If you do not have a proxy form and believe that you should have
one, or if you have any additional queries on voting, please
contact Neville Registrars Limited.
-Ends-
Enquiries:
e-therapeutics plc Tel: +44 (0)1993 883
125
Ali Mortazavi, CEO www.etherapeutics.co.uk
Karl Keegan, CFO
SP Angel Corporate Finance LLP
Nominated Adviser and Broker Tel: +44(0)20 3470
0470
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a
powerful computer-based approach to drug discovery, founded on its
industry-leading expertise in network biology to fully capture
disease complexity. The Company combines network science, machine
learning, artificial intelligence, statistics and big data with
expertise in drug discovery and development to transform the search
for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that
enables the rapid screening of millions of compounds and the
identification of small subsets that are enriched for highly active
hits. Its proprietary platform also has novel applications in
functional genomics, being able to analyse complex genetic
datasets, provide a deep understanding of pathological mechanisms
and distil actionable insights for the discovery of novel drugs,
biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic
drug discovery platform both in house and with partners, including
Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical
company.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAAMMBTMTTTBIB
(END) Dow Jones Newswires
May 21, 2021 02:00 ET (06:00 GMT)
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024